Datar Genetics Limited

datarpgx.com

Datar Genetics Limited is a NABL and ISO 9001:2008 accredited Centre for Excellence in Genetics for providing innovative, comprehensive clinical management solutions in the domain of molecular genomics. We have fully integrated sequencing, bio-informatics, human interface and interpretation platforms with State of the Art technological capability to provide clinical applications. We provide the widest range of genetic solutions and analytics of 300+ high impact investigations across the domains of Oncology, Cardiology, Neurology, Diabetes, High Resolution HLA Typing and Matching, Reproductive Genetics, Neonatal Screening, Pharmacogenetics and many more.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

VERSANTIS TO PRESENT POSITIVE PHASE 1B DATA AT AASLD FOR VS-01 IN PATIENTS WITH DECOMPENSATED CIRRHOSIS

Versantis | November 15, 2021

news image

Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, announced that positive Phase 1b clinical data from a study of its lead investigational, orphan-designated product, VS-01, in 12 hospitalized patients with decompensated liver cirrhosis will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting. The data show that VS-01 was safe and well tolerated in these patients, and demonstrated promi...

Read More

KYAN THERAPEUTICS EXCLUSIVELY ENTERS LICENSE AGREEMENT WITH GEORGETOWN UNIVERSITY FOR AI-POWERED CANCER DRUG DEVELOPMENT

KYAN Therapeutics | September 24, 2020

news image

KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has already commenced preclinical development of the lead candidate, which has been designated as KYAN-001, with early positive results. In vitro and in vivo studies of KYAN-001 have shown high efficacy for Multiple Myeloma and Prostate ...

Read More

MedTech

GENSCRIPT LAUNCHES EXPEDITED MRNA SERVICE FOR RESEARCH AND PRE-CLINICAL APPLICATIONS

Genscript | August 18, 2022

news image

GenScript USA Inc., the world's leading life-science research tools and services provider, announced the availability of a new research use only and pre-clinical messenger RNA synthesis service for biopharma research and development teams. By applying decades of experience in molecular biology, GenScript now offers a single-vendor gene-to-mRNA service that delivers custom mRNA within six to eight weeks. mRNA provides new therapeutic opportunities for a range of diseases, and s...

Read More

Cell and Gene Therapy

ELEVATEBIO ANNOUNCES ISSUANCE OF U.S. PATENT PROVIDING PROTECTION FOR RNA-GUIDED NUCLEASES IDENTIFIED THROUGH ITS LIFE EDIT GENE EDITING PLATFORM

ElevateBio | November 25, 2021

news image

ElevateBio, LLC, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced that the United States Patent and Trademark Office has issued US Patent No. 11,162,114 with an anticipated expiry date of June 23, 2040, inclusive of 384 days of patent term adjustment . This patent, issued to LifeEDIT Therapeutics, Inc. is the first to provide composition and methods of use protection for various RNA-guided nucleases in Life Edit’s gene editing...

Read More
news image

MedTech

VERSANTIS TO PRESENT POSITIVE PHASE 1B DATA AT AASLD FOR VS-01 IN PATIENTS WITH DECOMPENSATED CIRRHOSIS

Versantis | November 15, 2021

Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, announced that positive Phase 1b clinical data from a study of its lead investigational, orphan-designated product, VS-01, in 12 hospitalized patients with decompensated liver cirrhosis will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting. The data show that VS-01 was safe and well tolerated in these patients, and demonstrated promi...

Read More
news image

KYAN THERAPEUTICS EXCLUSIVELY ENTERS LICENSE AGREEMENT WITH GEORGETOWN UNIVERSITY FOR AI-POWERED CANCER DRUG DEVELOPMENT

KYAN Therapeutics | September 24, 2020

KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has already commenced preclinical development of the lead candidate, which has been designated as KYAN-001, with early positive results. In vitro and in vivo studies of KYAN-001 have shown high efficacy for Multiple Myeloma and Prostate ...

Read More
news image

MedTech

GENSCRIPT LAUNCHES EXPEDITED MRNA SERVICE FOR RESEARCH AND PRE-CLINICAL APPLICATIONS

Genscript | August 18, 2022

GenScript USA Inc., the world's leading life-science research tools and services provider, announced the availability of a new research use only and pre-clinical messenger RNA synthesis service for biopharma research and development teams. By applying decades of experience in molecular biology, GenScript now offers a single-vendor gene-to-mRNA service that delivers custom mRNA within six to eight weeks. mRNA provides new therapeutic opportunities for a range of diseases, and s...

Read More
news image

Cell and Gene Therapy

ELEVATEBIO ANNOUNCES ISSUANCE OF U.S. PATENT PROVIDING PROTECTION FOR RNA-GUIDED NUCLEASES IDENTIFIED THROUGH ITS LIFE EDIT GENE EDITING PLATFORM

ElevateBio | November 25, 2021

ElevateBio, LLC, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced that the United States Patent and Trademark Office has issued US Patent No. 11,162,114 with an anticipated expiry date of June 23, 2040, inclusive of 384 days of patent term adjustment . This patent, issued to LifeEDIT Therapeutics, Inc. is the first to provide composition and methods of use protection for various RNA-guided nucleases in Life Edit’s gene editing...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us